Industry
Biotechnology
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 1:11 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 3:57 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 10:33 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:04 am
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 9:19 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 11:19 am
Portfolio Pulse from Benzinga Insights
May 14, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 11:01 am
Portfolio Pulse from Benzinga Newsdesk
April 18, 2024 | 3:42 pm
Portfolio Pulse from Benzinga Newsdesk
April 04, 2024 | 12:03 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.